TerminatedPhase 1/2

A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Stopped: Lack of Efficacy

United States4 participantsStarted 2006-09

Plain-language summary

Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are in need of a vitrectomy. Exclusion Criteria: * A PVD in the study eye as assessed by the investigator using ophthalmic and alternative examination techniques. * A history of vitrectomy in the study eye. * A media opacity that precludes quality examination of the vitreous and fundus in the study eye.

What they're measuring

Presence of a Posterior Vitreous Detachment (PVD)

Timeframe: 14 days

Trial details

NCT IDNCT00347646

SponsorBausch & Lomb Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-05

View on ClinicalTrials.gov More Vitreoretinal Traction Syndrome trials